The Acute Stroke Recruitment Bottleneck and Electronic Informed Consent

Acute ischemic stroke presents a formidable challenge in clinical research because therapeutic windows close rapidly. Consequently, investigators must complete eligibility screening, neurological examinations, neuroimaging, and consent discussions within minutes. In this time-critical setting, traditional paper-based workflows frequently delay enrollment or cause eligible candidates to miss experimental therapies entirely. To address these persistent hurdles, researchers increasingly turn to electronic informed consent to streamline participant intake. The platform allows investigators to present trial materials electronically through intuitive digital interfaces, thereby modernizing communication during hyperacute emergencies. Neurological deficits such as aphasia, cognitive impairment, or hemiparesis often prevent acute stroke patients from providing valid consent themselves. Therefore, clinical teams must swiftly contact legally authorized representatives who may reside far from the hospital. Electronic solutions bridge this geographic divide by transmitting multimedia documents, embedded educational videos, and digital signature forms directly to personal smartphones or tablets. Furthermore, these platforms provide timestamped verification, ensuring that surrogate decision-makers receive transparent clinical trial disclosures without wasting vital brain tissue. As digital healthcare ecosystems mature globally, integrating digital workflows offers an indispensable pathway toward equitable and swift participant recruitment.

Key Recruitment Findings from the MOST Trial

The Multi-Arm Optimization of Stroke Thrombolysis trial, known as the MOST trial, evaluated adjuvant argatroban or eptifibatide alongside standard intravenous thrombolysis in acute ischemic stroke patients. In a secondary post hoc analysis, investigators scrutinized participant recruitment patterns across 57 participating medical centers throughout the United States. Between October 2019 and July 2023, the multicenter phase III trial enrolled 514 participants. Participating trial sites maintained the operational flexibility to implement conventional paper documentation or utilize digital consenting systems for every individual enrollment. Overall, investigators deployed digital consenting for 173 participants, representing 33.7% of the total trial cohort. Notably, 32 of the 57 study sites utilized digital workflows at least once during the recruitment period. Centers adopting the digital consent platform demonstrated a significantly higher median recruitment volume than non-adopting institutions, achieving 7.5 participants compared to merely 3 participants. Moreover, the adoption curve expanded steadily over the study duration, illustrating growing investigator familiarity and technical comfort. These observational findings strongly suggest that integrating electronic consenting mechanisms fosters higher site-level enrollment productivity without disrupting standard clinical stroke algorithms.

Facilitating Remote Surrogacy Without Procedural Delays

Surrogate consent remains a universal necessity in acute stroke research because sudden neurological disability impairs patient decision-making capacity. Fortunately, digital systems fundamentally reshape this dynamic by facilitating seamless remote interaction between clinical coordinators and families. In the MOST trial analysis, sites utilizing digital consent engaged significantly more remote legally authorized representatives than conventional paper sites. Traditional paper processes often require cumbersome facsimile transmissions, secure physical couriers, or scanned email attachments, which consume invaluable clinical minutes. In contrast, cloud-based digital platforms deliver interactive documents instantly to mobile devices across different time zones. Family members can review institutional review board-approved summaries, ask detailed questions via secure videoconferencing, and submit authenticated electronic signatures within minutes. Importantly, the researchers confirmed that baseline neuroimaging-to-randomization intervals remained comparable between digital consent and traditional paper modalities. Thus, digital recruitment protocols did not introduce operational latency into time-sensitive emergency treatment pathways. By eliminating physical travel requirements for surrogates, the platform actively preserves stroke trial eligibility while maintaining robust ethical and clinical transparency. Consequently, bedside clinicians enroll eligible individuals rapidly without compromising paramount door-to-needle thrombolysis metrics.

Data Quality, Error Reduction, and Regulatory Compliance

Regulatory scrutiny in emergency research demands flawless documentation, yet paper consent forms frequently suffer from inadvertent human oversights. Typical paper errors include missing checkmarks, absent date stamps, uninitialed pages, or outdated document versions. In the MOST trial evaluation, research teams using digital platforms demonstrated marked improvements in consent documentation adherence. Digital systems employ automated workflow validations that prevent signature submission if users skip required fields or omit essential acknowledgments. Consequently, sites using digital tools generated far fewer data clarification requests from central trial monitors. In addition, these sites experienced zero significant increases in reportable consent-related unanticipated events, demonstrating strict regulatory compliance. The automated archiving feature instantly deposits time-stamped, unalterable digital records into secure, audit-ready cloud repositories. Institutional review boards and regulatory inspectors can inspect these comprehensive audit trails at any point during trial execution. Therefore, digital consent simultaneously protects patient rights and minimizes costly monitoring queries for academic research coordinators and principal investigators. This technological transition guarantees that research teams maintain rigorous quality standards while coordinating emergency acute care.

Implications for Acute Stroke Research in India and Global Practice

The findings from the MOST trial provide vital insights for investigators expanding clinical stroke research in India and developing healthcare ecosystems. The Indian Council of Medical Research and national regulatory authorities emphasize robust participant protection through informed consent, including validated electronic modalities. Because stroke incidence is rising across South Asia, tertiary centers often face immense emergency patient volumes alongside complex familial dynamics. Relatives frequently make collective medical decisions while coordinating transit from rural districts to urban comprehensive stroke centers. Implementing verified digital consenting platforms enables Indian researchers to bridge severe logistical divides and engage dispersed family decision-makers rapidly. Furthermore, automated digital workflows drastically reduce documentation noncompliance, ensuring adherence to the New Drugs and Clinical Trials Rules. Local ethics committees can review electronic templates that incorporate regional vernacular translations and culturally sensitive visual explanations. Therefore, adopting electronic consent modernizes trial infrastructure, accelerates patient enrollment into life-saving thrombolytic and neuroprotective trials, and strengthens the overall credibility of academic clinical research across emerging economies. Ultimately, digital tools establish a scalable pathway toward truly equitable clinical investigation.

Frequently Asked Questions

How does electronic informed consent improve enrollment rates in acute stroke trials?

Electronic informed consent improves enrollment rates by allowing rapid, remote engagement with legally authorized representatives. Because stroke impairs patient communication, investigators frequently require surrogate permission. Digital platforms transmit multimedia consent documents instantly to family smartphones, eliminating transit delays and allowing surrogates to authorize participation within hyperacute therapeutic windows.

Does implementing eConsent cause treatment delays during acute ischemic stroke emergencies?

Evidence shows that electronic consent does not cause treatment delays during acute stroke emergencies. In the MOST trial, baseline neuroimaging-to-randomization intervals remained identical between electronic and paper workflows. Automated digital interfaces enable prompt remote reviews and instant signatures, ensuring that patients receive timely investigational therapies without compromising acute care protocols.

What regulatory standards govern electronic informed consent execution in Indian clinical trials?

In India, electronic informed consent must comply with the New Drugs and Clinical Trials Rules and Indian Council of Medical Research guidelines. Platforms must ensure participant confidentiality, verified electronic authentication, tamper-evident audit trails, and institutional ethics committee approval. Systems must also provide regional language versions to ensure voluntary, fully understood participant participation.

Disclaimer: This content is for informational and educational purposes only and should not be considered medical advice. Healthcare professionals must exercise independent clinical judgment. Refer to the latest local and national guidelines for clinical practice.

References

1. Davis SI et al. Electronic Informed Consent in the Multi-Arm Optimization of Stroke Thrombolysis Trial. Stroke. 2025 Jul. doi: 10.1161/STROKEAHA.124.049369. PMID: 40235446.


2. Broderick JP, Grotta JC, Jauch EC, et al. Recruitment in Acute Stroke Trials: Challenges and Potential Solutions. Stroke. 2023 Feb;54(2):632-638. doi: 10.1161/STROKEAHA.122.040071.


3. Indian Council of Medical Research. National Ethical Guidelines for Biomedical and Health Research Involving Human Participants. New Delhi: ICMR; 2017.